DiscoverGRACEcast Lung Cancer VideoWhat Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

Update: 2014-07-08
Share

Description

"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

cancerGRACE - H. Jack West, MD